Combination of long-acting HIV fusion inhibitor albuvirtide and LPV/r showed potent efficacy in HIV-1 patients

BACKGROUND: Long acting antiretroviral drugs represent a promising approach for chronic treatment of HIV infection. Here, we study the efficacy and safety of albuvirtide (ABT), an HIV-1 fusion inhibitor with a half life of 11–12 days in human. METHODS: ABT was evaluated in a 7-week, open-label and r...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Hongwei, Jin, Ronghua, Yao, Cheng, Zhang, Tong, Wang, Meixia, Xia, Wei, Peng, Haiyan, Wang, Xiaojuan, Lu, Rongjian, Wang, Changjin, Xie, Dong, Wu, Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4748529/
https://www.ncbi.nlm.nih.gov/pubmed/26865854
http://dx.doi.org/10.1186/s12981-016-0091-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4748529/
https://www.ncbi.nlm.nih.gov/pubmed/26865854
http://dx.doi.org/10.1186/s12981-016-0091-1

Ejemplares similares